ZBIO vs DYN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DYN Captures Institutional Edge (2โ2 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Dyne Therapeutics, Inc. Common Stock (DYN) driven by superior Valuation, Growth & Margin while ZBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus DYN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against DYN sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZBIO | DYN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $3.2B | Larger Scale | DYN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | DYN |
| Operating Margin (TTM) Profitability | -2747.5% | 0.0% | Higher Margin | DYN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -265.1% | -74.6% | Higher ROE | DYN |
| 52-Week Range Position Momentum | 46% ($14โ$45) | 20% ($14โ$27) | Stronger Trend | ZBIO |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 59% Vol | 1.71ฮฒ ยท 58% Vol | Lower Realized Risk | DYN |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 47.5 / 100 (HOLD) | Higher Composite | ZBIO |